Nebivolol Glenmark Arzneimittel (Nebivolol Hydrochloride)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. It also stimulates nitric oxide release from the endothelium, causing vasodilation and lowering peripheral vascular resistance, which together contribute to reduced blood pressure.

The appropriate dose of nebivolol is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any comorbidities. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nebivolol is a highly selective β1‑blocker with additional nitric‑oxide‑mediated vasodilatory properties, which may offer better tolerability regarding metabolic effects and fewer central nervous system side effects compared with non‑selective beta‑blockers. Clinical choice depends on patient profile, comorbidities and physician judgment.

Nebivolol tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Nebivolol is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, marked hypotension, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, difficulty breathing, or swelling of the face or throat.

Nebivolol is contraindicated in patients with known hypersensitivity to the drug, severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and in those with uncompensated heart failure. Caution is also advised for individuals with asthma, severe hepatic impairment, or uncontrolled heart failure.